(Q34750106)

4 August 2017

1 reference

title

Interferon beta treatment in relapsing-remitting multiple sclerosis. A review (English)

1 reference

relapsing-remitting multiple sclerosis

4 August 2017

0 references

0 references

author name string

Nikolaos Grigoriadis

series ordinal

1

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Clinical Neurology and Neurosurgery

4 August 2017

published in

1 reference

4 August 2017

volume

104

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

251-258

1 reference

MS: a CNS and systemic autoimmune disease

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Neuropsychological effects of interferon ?-1a in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Magnetic resonance imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Axonal damage in acute multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Misdiagnosis of multiple sclerosis and beta-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Serial MRI, VEP, SEP and biotesiometry in acute optic neuritis: value of baseline results to predict the development of new lesions at one year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Early prognostic factors for disability in multiple sclerosis, a European multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Interferon beta-1a during a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Diagnostic criteria for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900048-3

7 January 2021

10.1016/S0303-8467(02)00048-3

Identifiers

DOI

1 reference

4 August 2017

1 reference